LCM
Lynx1 Capital Management Portfolio holdings
AUM
$346M
This Quarter Return
-0.43%
1 Year Return
-2.97%
3 Year Return
+1,498.67%
5 Year Return
–
10 Year Return
–
AUM
$277M
AUM Growth
+$277M
(-29%)
Cap. Flow
-$172M
Cap. Flow
% of AUM
-62.18%
Top 10 Holdings %
Top 10 Hldgs %
98.86%
Holding
22
New
6
Increased
5
Reduced
4
Closed
5
Top Buys
| 1 |
Stoke Therapeutics
STOK
|
$20.1M |
| 2 |
C4 Therapeutics
CCCC
|
$15M |
| 3 |
GH Research
GHRS
|
$7.65M |
| 4 |
Cullinan Oncology
CGEM
|
$6.58M |
| 5 |
Allogene Therapeutics
ALLO
|
$5.19M |
Top Sells
| 1 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$89.3M |
| 2 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$85.7M |
| 3 |
Merus
MRUS
|
$17.9M |
| 4 |
Cabaletta Bio
CABA
|
$11.9M |
| 5 |
SLN
Silence Therapeutics
SLN
|
$11.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Merus
MRUS
$4.98B
| $71.4M | 25.76% | 1,206,707 -302,300 | -20% | -$17.9M |
|
|
2
Stoke Therapeutics
STOK
$1.08B
| $70.1M | 25.27% | 5,185,191 +1,488,371 | +40% | +$20.1M |
|
|
3
GH Research
GHRS
$837M
| $46.3M | 16.69% | 3,966,726 +656,163 | +20% | +$7.65M |
|
|
4
C4 Therapeutics
CCCC
$185M
| $31.8M | 11.47% | 6,880,527 +3,245,865 | +89% | +$15M |
|
5
TScan Therapeutics
TCRX
$102M
| $30.6M | 11.03% | 5,224,600 | – | – |
|
|
6
Cullinan Oncology
CGEM
$445M
| $6.58M | 2.37% | +377,323 | New | +$6.58M |
|
|
7
Allogene Therapeutics
ALLO
$251M
| $5.19M | 1.87% | +2,228,295 | New | +$5.19M |
|
|
LBPH
8
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $4.52M | 1.63% | +167,317 | New | +$4.52M |
|
9
Passage Bio
PASG
$22.7M
| $4.02M | 1.45% | 5,057,629 +211,758 | +4% | +$168K |
|
|
10
Cabaletta Bio
CABA
$133M
| $3.68M | 1.33% | 492,103 -1,590,870 | -76% | -$11.9M |
|
11
iBio
IBIO
$16.1M
| $1.77M | 0.64% | 840,763 +240,763 | +40% | +$508K |
|
|
NEUP
12
Neuphoria Therapeutics Inc. Common Stock
NEUP
$21.3M
| $460K | 0.17% | 599,673 -214,794 | -26% | -$165K |
|
|
PVLA
13
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $427K | 0.15% | 43,499 -8,735,663 | -100% | -$85.7M |
|
14
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $177K | 0.06% | +9,500 | New | +$177K |
|
|
CNTA
15
Centessa Pharmaceuticals
CNTA
$2.25B
| $157K | 0.06% | 17,400 | – | – |
|
16
Korro Bio
KRRO
$217M
| $129K | 0.05% | +3,800 | New | +$129K |
|
17
VYNE Therapeutics
VYNE
$8.16M
| $31.9K | 0.01% | +16,194 | New | +$31.9K |
|
18
Nektar Therapeutics
NKTR
$568M
| – | – | -2,068,842 | Closed | -$1.93M |
|
|
SLN
19
Silence Therapeutics
SLN
$227M
| – | – | -526,642 | Closed | -$11.4M |
|
|
ALPN
20
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| – | – | -2,253,183 | Closed | -$89.3M |
|
|
KNTE
21
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| – | – | -1,981,106 | Closed | -$5.27M |
|
|
AUTL
22
Autolus Therapeutics
AUTL
$399M
| – | – | -1,390,160 | Closed | -$8.87M |
|